Research Article

A spatial-temporal description of the SARS-CoV-2 infections in Indonesia during the first six months of outbreak

Dewi Nur Aisyah1,2*, Chyntia Aryanti Mayadewi1, Haniena Diva1, Zisis Kozlakidis3, Siswanto4, Wiku Adisasmito1,5,6

1 Indonesia One Health University Network, Depok, West Java, Indonesia, 2 Institute of Epidemiology and Health Care, University College London, London, United Kingdom, 3 World Health Organization, International Agency for Research on Cancer, Lyon, France, 4 National Institute of Health Research and Development, Jakarta, Indonesia, 5 Faculty of Public Health, Universitas Indonesia, Depok, West Java, Indonesia, 6 Indonesia National Task Force for the Acceleration of COVID-19, Jakarta, Indonesia

* dewi.aisyah@indohun.org

Abstract

Background

Since the first cases reported in Wuhan, China, in December 2019, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide. In Indonesia, the first case was reported in early March 2020, and the numbers of confirmed infections have been increasing until now. Efforts to contain the virus globally and in Indonesia are ongoing. This is the very first manuscript using a spatial-temporal model to describe the SARS-CoV-2 transmission in Indonesia, as well as providing a patient profile for all confirmed COVID-19 cases.

Method

Data was collected from the official website of the Indonesia National Task Force for the Acceleration of COVID-19, from the period of 02 March 2020–02 August 2020. The data from RT-PCR confirmed, SARS-CoV-2 positive patients was categorized according to demographics, symptoms and comorbidities based on case categorization (confirmed, recovered, dead). The data collected provides granular and thorough information on time and geographical location for all 34 Provinces across Indonesia.

Results

A cumulative total of 111,450 confirmed cases of were reported in Indonesia during the study period. Of those confirmed cases 67.79% (75,551/111,450) were shown as recovered and 4.83% (5,382/111,450) of them as died. Patients were mostly male (50.52%; 56,300/111,450) and adults aged 31 to 45 years old (29.73%; 33,132/111,450). Overall patient presentation symptoms of cough and fever, as well as chronic disease comorbidities were in line with previously published data from elsewhere in South-East Asia. The data reported here, shows that from the detection of the first confirmed case and within a short time period of 40 days, all the provinces of Indonesia were affected by COVID-19.
Conclusions

This study is the first to provide detailed characteristics of the confirmed SARS-CoV-2 patients in Indonesia, including their demographic profile and COVID-19 presentation history. It used a spatial-temporal analysis to present the epidemic spread from the very beginning of the outbreak throughout all provinces in the country. The increase of new confirmed cases has been consistent during this time period for all provinces, with some demonstrating a sharp increase, in part due to the surge in national diagnostic capacity. This information delivers a ready resource that can be used for prediction modelling, and is utilized continuously by the current Indonesian Task Force in order to advise on potential implementation or removal of public distancing measures, and on potential availability of healthcare capacity in their efforts to ultimately manage the outbreak.

Introduction

Since the first cases reported from Wuhan, China, in December 2019, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide. According to the World Health Organization (WHO) by August 23, 2020, the number of total confirmed infected cases across the world stood at 23,057,288, while the total deaths reached 800,906 [1]. India and Indonesia, the two most populous countries in South-East Asia, have reported and continue to report large numbers of cases (3,044,940 and 151,498, respectively, as of August 23, 2020) [1]. In Indonesia, the first case was reported in March 02, 2020.

Efforts to contain the virus globally are ongoing. However, given the many uncertainties regarding the numbers of asymptomatic infections, as well as the rate of pathogen transmissibility, the effectiveness of these efforts is not adequately quantified yet. It has been demonstrated that the reproductive number of COVID-19 is higher compared to previous coronavirus outbreaks [2], and in addition a large proportion of infected cases seem to be asymptomatic [3]. Therefore, it is not surprising that the number of new confirmed cases and COVID-19-related deaths, are still rising in most countries, including in Indonesia.

In order to reduce the number of new cases, governments have relied on classical public health measures to curb the rate of spread of the epidemic. The primary goal of such public health measures (for example quarantine, social distancing, and community containment) has been consistently to prevent person-to-person transmission by separating and/or distancing people [4, 5]. Even though Indonesia implemented several control measures (including physical distancing, home quarantine, public messaging for the regular washing of hands and the wearing of masks in public, local travel restrictions, etc), there is still an upward trend in the number of new cases confirmed nationally. According to the WHO, the virus spread in Indonesia can be categorized as ‘community transmission’ [6], because of the inability to relate confirmed cases through chains of transmission for a large number of cases. Thus, understanding the transmission mechanisms and patterns forms a key question [7, 8].

A foundational first step in developing a strategy and predictive modelling for COVID-19 in Indonesia is to analyze the numbers of confirmed cases, along with their time occurrence [9]. This spatial-temporal reasoning model, is widely useful to obtain information about identifying high risk areas, supporting monitoring and prevention efforts [10], and to predict the epidemic’s trajectory [11].

To better understand the nature and spread of COVID-19 infection in Indonesia, we used spatio-temporal reasoning model to analyze the national data between March and August.
2020. Data was collected from the Indonesia National Task Force for the Acceleration of COVID-19, from the period of March 2\textsuperscript{nd} 2020 to August 2\textsuperscript{nd} 2020. The data provides granular information of COVID-19 surveillance in 34 Provinces across Indonesia and delivers a ready resource that can be used for future prediction modelling.

\textbf{Methods}

\textbf{Study area}

Geographically, Indonesia is in South-East Asia, lying between the Indian Ocean and the Pacific Ocean (lat: 5’00’ N, lon: 120’00’ E). It is an archipelagic country comprising 5 major islands (Sumatera, Kalimantan, Java, Sulawesi, and Papua) and thousands of smaller islands. Indonesia is located adjacent to the equator line, and is a tropical region with 2 seasons: the rainy (October–March) and dry seasons (April–September).

Indonesia is administratively divided into 34 provinces and 514 cities and regencies, with independent local governments and parliamentary bodies. It has 10,138 public health centers (PUSKESMAS—primary healthcare facilities) and 2,902 hospitals (tertiary healthcare facilities) spread across these provinces, of which 132 hospitals are designated as national referral centres for the treatment of COVID-19 [12]. The total population of Indonesia stands at 267,663,435 (2018) with females representing 50% of the population [13], and the median age around 30 years [14].

\textbf{Data collection}

Data for this study was obtained from the website of the Indonesian National Task Force for the Acceleration of COVID-19 Response (www.covid19.go.id). Data obtained included details of confirmed cases (i.e. demographics, presenting symptoms and comorbidities), and treatment outcomes (recovery or death) in all 34 provinces between 2\textsuperscript{nd} March 2020 and 2\textsuperscript{nd} August 2020. Use of the data, which was anonymized, aggregated, and at the population level was permitted by the Indonesian Ministry of Health under Regulation Number 45 (2014), Article 3, paragraph 1 and 2.

The Indonesian sampling and testing strategy aims to investigate all cases and clusters of COVID-19. The aim is for a minimum 90% of suspected cases to be isolated and to carry out a specimen collection in less than 48 hours since the appearance symptoms, so that secondary transmission is avoided as much as possible. The specimens should be sent to the referral laboratories and a result should be received within 72 hours, during which time individuals are advised to self-isolate. The outcomes of the epidemiological and laboratory investigations are required to be reported nationally on a daily basis to the Ministry of Health and the National COVID-19 Taskforce through dedicated data collection channels [15].

Samples are collected via nasopharyngeal (NP) or oropharyngeal (OP) swabs or sputum or serum, according to the Indonesian Ministry of Health protocols [15]. Mostly NP and OP swabs have been collected to date, for diagnostic testing performed by reverse transcriptase PCR (RT-PCR).

\textbf{Data analysis}

The collected data was classified according to the recovered/death status to describe the patients’ characteristics. A univariate logistic regression was performed SPSS, version 20 (SPSS Inc., Chicago, IL, USA) to identify factors potentially associated with COVID-19 mortality. The adjusted odd ratios and 95% confidence intervals are shown for COVID-19 mortality risk factors based on sex, age group, and the geographical location (including only the 5 largest
The $\chi^2$ test was used to analyse the collected data about the impact of sex, region, and age group, as previously described [17].

Further descriptive presentation of the data was taken in 8 priority provinces, (Jakarta, West Java, East Java, Central Java, South Sulawesi, North Sulawesi, South Kalimantan, and Papua), in accordance with the recovered/death status, age group and sex characteristics.

For the spatio-temporal analysis, the number of new confirmed cases in each province were added into an xy axis graph and the amount of cases were differentiated by colours. To show the cumulative numbers of cases, the numbers were mapped by using available map customization application (https://mapchart.net/) [18]. The heat maps were created according to a window of 22 weeks follow-up.

Results

A cumulative total of 111,450 confirmed cases of COVID-19 were reported in Indonesia between March 2nd and August 2nd 2020. 67.79% (75,551/111,450) of those confirmed cases were shown as recovered and 4.83% (5,382/111,450) of them as died (see Table 1). Among those reported as SARS-CoV-2 RT-PCR positive in Indonesia 50.52% were males (56,300/111,450) and adults aged 31 to 45 years old (29.73%; 33,132/111,450). There was no statistical significance observed in the sex ratio of confirmed cases ($p = 0.339$). However, sex was statistically significant for the recovered and death categories ($p < 0.001$ in both cases), where greater relative proportions of females were recorded as recovered: the female group (68.05%; 35,352/51,948) compared to the male group (67.45%; 37,977/56,300). The death percentage is also greater in male (5.59%; 3,146/56,300) than female confirmed cases (4.09%; 2,127/51,948; $p < 0.001$). Although adults aged 31–45 years old are shown to be more prone to be infected compared to other age groups, the elderly ($\geq 60$ years old) had the highest proportion of death (16.46%; 2,041/12,396; $p < 0.001$) and lowest proportion of recovery across both genders (60.29%; 7,474/12,396; $p < 0.001$), summarised in Table 2.

The most common initial symptoms reported as occurring among the confirmed infected population were cough (2.58%; 2,871/111,450), followed by a history of fever (1.71%; 1,906/111,450) and persistent fever (1.41%; 1,573/111,450). Not all of the patients suffered from difficulty to breathe (1.24%; 1,384/111,450). A number of confirmed cases also reported a clinical history of hypertension (0.63%; 700/111,450) and diabetes mellitus (0.43%; 478/111,450). The major comorbidities found among patients who were registered as dead included kidney disease (51.81; 43/83), heart disease (38.41%; 106/168), and immunocompromised patients (33.33%; 7/14). However, caution needs to be exercised when interpreting the above data, as the records have variable levels of completion for the initial symptoms categories and as such could not support further statistical analyses. The very high level of incomplete data (in some cases close to 90%, Table 2) and the high variability of completion between different comorbidity categories has prevented the further analyses of comorbidities.

The 5 provinces with the highest number of COVID-19 confirmed cases (as a % of the national total) were East Java (20.19%; 22,504/111,450), DKI Jakarta (19.87%; 22,144/111,450), Central Java (8.73%; 9,732/111,450), South Sulawesi (8.66%; 9,647/111,450), and West Java (5.96%; 6,637/111,450). These five provinces contributed over than 60% of the national cases. On the other hand, based on the reported case incidence, the top 5 provinces were DKI Jakarta (204.16 per 100,000 population), South Kalimantan (153.91 per 100,000 population), South Maluku (119.05 per 100,000 population), Gorontalo (108.75 per 100,000 population), and South Sulawesi (102.33 per 100,000 population). The recorded incidence in Jakarta as compared to the other main islands was much higher and statistically significant across all case categories (confirmed, recovered, death; $p < 0.001$ for all).
Table 1. Characteristics of total national demographics, symptoms and comorbidity based on case categorization (confirmed, recovered, death) in Indonesia from March 2nd - August 2nd 2020.

| Characteristics | Confirmed (n) | % | Active Cases (n) | % to total confirmed | Recovered (n) | % to total confirmed | Death (n) | % to total confirmed |
|-----------------|--------------|---|-----------------|---------------------|--------------|---------------------|----------|---------------------|
| All             | 111,450      |    | 30,517          | 27.38               | 75,551       | 67.79               | 5,382    | 4.83                |
| Sex             |              |    |                 |                     |              |                     |          |                     |
| Male            | 56,300       | 50.52 | 15,178          | 26.96               | 37,977       | 67.45               | 3,146    | 5.59                |
| Female          | 51,948       | 46.61 | 14,469          | 27.85               | 35,352       | 68.05               | 2,127    | 4.09                |
| Missing         | 3,202        | 2.87  | 870             | 27.17               | 2,222        | 69.39               | 110      | 3.44                |
| Age Group (y.o) |              |    |                 |                     |              |                     |          |                     |
| 0–5             | 2,507        | 2.25  | 733             | 29.24               | 1,723        | 68.73               | 51       | 2.03                |
| 6–18            | 7,197        | 6.46  | 1,969           | 27.36               | 5,169        | 71.82               | 59       | 0.82                |
| 19–30           | 24,557       | 22.03 | 7,210           | 29.36               | 17,108       | 69.67               | 239      | 0.97                |
| 31–45           | 33,132       | 29.73 | 9,359           | 28.25               | 22,987       | 69.38               | 786      | 2.37                |
| 46–59           | 26,000       | 23.33 | 6,722           | 25.85               | 17,238       | 66.30               | 2,039    | 7.84                |
| ≥60             | 12,396       | 11.12 | 2,881           | 23.24               | 7,474        | 60.29               | 2,041    | 16.46               |
| Missing         | 1,777        | 1.59  | 1,643           | 92.46               | 1,207        | 67.92               | 68       | 3.83                |
| Initial Symptoms|              |    |                 |                     |              |                     |          |                     |
| Cough           | 2,871        | 2.58  | 70              | 2.44                | 2,400        | 83.59               | 401      | 13.97               |
| History of fever| 1,906        | 1.71  | 18              | 0.94                | 1,589        | 83.37               | 299      | 15.69               |
| Fever           | 1,573        | 1.41  | 78              | 4.96                | 1,254        | 79.72               | 241      | 15.32               |
| Difficulty to breathe | 1,384 | 1.24 | 21 | 1.52 | 1,001 | 72.33 | 362 | 26.16 |
| Fatigue         | 1,049        | 0.94  | 6               | 0.57                | 890          | 84.84               | 121      | 11.53               |
| Cold            | 1,573        | 1.41  | 38              | 2.42                | 1,253        | 79.66               | 241      | 15.32               |
| Sore throat     | 1,010        | 0.91  | 17              | 1.68                | 832          | 82.38               | 161      | 15.94               |
| Headache        | 889          | 0.80  | 6               | 0.67                | 740          | 83.24               | 143      | 16.09               |
| Nausea          | 769          | 0.69  | 6               | 0.78                | 640          | 83.22               | 123      | 15.99               |
| Muscle cramp    | 613          | 0.55  | 6               | 0.98                | 500          | 81.57               | 107      | 17.46               |
| Shivering       | 367          | 0.33  | 21              | 5.72                | 271          | 73.84               | 75       | 20.44               |
| Diarrhoea       | 295          | 0.26  | 2               | 0.68                | 244          | 82.71               | 49       | 16.61               |
| Stomach ache    | 304          | 0.27  | 4               | 1.32                | 248          | 81.58               | 52       | 17.11               |
| Missing         | 104,150      | 93.45 | 30,336          | 29.13               | 68,988       | 67.24               | 4,825    | 4.63                |
| Total Comorbidities |          |    |                 |                     |              |                     |          |                     |
| None            | 5,246        | 4.71  | 140             | 2.67                | 4,927        | 93.92               | 178      | 3.39                |
| One             | 1,166        | 1.05  | 16              | 1.37                | 786          | 67.41               | 186      | 15.95               |
| Two             | 312          | 0.28  | 4               | 1.28                | 200          | 64.1                | 108      | 34.62               |
| Three or more   | 113          | 0.1   | 0               | 0                   | 55           | 48.67               | 58       | 51.33               |
| Missing         | 104,791      | 94.03 | 30,357          | 28.97               | 69,582       | 66.4                | 4,852    | 4.63                |
| Type of Comorbidity |          |    |                 |                     |              |                     |          |                     |
| Hypertension    | 700          | 0.63  | 9               | 1.29                | 509          | 72.71               | 182      | 26.00               |
| Diabetes mellitus| 478          | 0.43  | 5               | 1.05                | 311          | 65.06               | 162      | 33.89               |
| Heart disease   | 276          | 0.25  | 2               | 0.72                | 168          | 60.87               | 106      | 38.41               |
| COPD            | 139          | 0.12  | 10              | 7.19                | 105          | 75.54               | 34       | 24.46               |
| Other respiratory disease | 89 | 0.08 | 2 | 2.25 | 63 | 70.79 | 24 | 26.97 |
| CKD             | 83           | 0.07  | 0               | 0                   | 40           | 48.19               | 43       | 51.81               |
| TB              | 26           | 0.02  | 0               | 0                   | 19           | 73.08               | 7        | 26.92               |
| Pregnancy       | 68           | 0.06  | 6               | 8.82                | 56           | 82.35               | 3        | 4.41                |
| Asthma          | 33           | 0.03  | 0               | 0                   | 28           | 84.85               | 5        | 15.15               |
| Cancer          | 21           | 0.02  | 0               | 0                   | 14           | 66.67               | 7        | 33.33               |
| Immunocompromise| 21           | 0.02  | 0               | 0                   | 14           | 66.67               | 7        | 33.33               |

(Continued)
The characteristics of patients in Jakarta, West Java, East Java, Central Java, North Sumatera, South Kalimantan, South Sulawesi, and Papua for age group, sex, and recovered/death status are shown in Fig 1A and 1B, as these provinces had the highest reported COVID-19 incidence. The overall weekly related reporting of cases and deaths is shown in Fig 1C.

The first two RT-PCR confirmed cases of SARS-CoV-2 were identified on March 02, 2020 in Jakarta. The third positive confirmed case was found in West Java on March 03 and another case in Banten on March 06, 2020. The spatial-temporal results show that all provinces in Indonesia experienced confirmed COVID-19 cases (Figs 2 and 3) within 41 days since the first confirmed case was reported (March 2nd to April 10th 2020). Generally, Jakarta reported consistently the highest number of new confirmed cases per day (>100 per day). Even though the date of onset for the different outbreaks was different among different provinces (Fig 2), once a case was confirmed, new cases followed immediately afterwards.

The heat map (Fig 3) shows the development of transmission in the 34 provinces across Indonesia within this period of approximately 6 months (5 months and 2 weeks). During the first week, the confirmed cases were concentrated only in West Java, Jakarta, and Banten. The following week, new confirmed cases were reported in East Kalimantan, and a few days later the spread of new infections was increasing rapidly both in the western and eastern part of Indonesia, adding 18 new provinces with reported cases. By the sixth week, confirmed cases were noted across all provinces. Within the last 2 weeks of the period studied, cumulative cases of >100 confirmed cases had occurred in several provinces, leaving Jakarta as the most infected area with >1000 cases by the end of the last week (Fig 4).

Discussion

Overall, our study shows that the RT-PCR confirmed SARS-CoV-2 infections in Indonesia were more prevalent in males with age range between 31–45 years old, most presenting with self-reported fever and cough symptoms, and having a prior clinical history of hypertension and/or of diabetes mellitus. The highest increase in the absolute amount of new confirmed cases was shown in Jakarta, West Java, Central Java, East Java, and South Sulawesi; while other provinces showed a comparatively modest reporting of new confirmed cases every day. By the sixth week of follow-up all provinces in Indonesia were affected by confirmed COVID-19 cases. Similar transmission patterns were seen in 5 major cities in China, not geographically adjacent to Wuhan [19].

The characteristics of Indonesian COVID-19 patients were similar to those reported for China and Italy [20–22], with cough and fever/history of fever being the most frequent symptoms [20, 23] and within similar age groups [23, 24]. Males were more prevalent to a worse clinical outcome as compared to females as in other studies from China, Italy and the USA [20, 25, 26]. The elderly population of above 60 years old (19.8%; 326/1,647) showed the highest mortality, in line with observations in other countries [20–22]. Thus, current observations in Indonesia are aligned with previously published observations [27] and show similar patient profiles from other parts of South-East Asia [28–31]. Furthermore, as Indonesia reports one of the highest chronic kidney disease incidences in South-East Asia, affecting over 8% of the over

Table 1. (Continued)

| Characteristics | Confirmed (n) | % | Active Cases (n) | % to total confirmed | Recovered (n) | % to total confirmed | Death (n) | % to total confirmed |
|-----------------|--------------|---|------------------|----------------------|--------------|----------------------|----------|----------------------|
| Liver disease   | 28           | 0.03| 0                | 0.00                 | 20           | 71.43                | 8        | 28.57                |
| Missing         | 104,791      | 94.03| 30,357           | 28.97                | 69,582       | 66.4                | 4,852    | 4.63                 |

https://doi.org/10.1371/journal.pone.0243703.t001

The characteristics of patients in Jakarta, West Java, East Java, Central Java, North Sumatera, South Kalimantan, South Sulawesi, and Papua for age group, sex, and recovered/death status are shown in Fig 1A and 1B, as these provinces had the highest reported COVID-19 incidence. The overall weekly related reporting of cases and deaths is shown in Fig 1C.

The first two RT-PCR confirmed cases of SARS-CoV-2 were identified on March 02, 2020 in Jakarta. The third positive confirmed case was found in West Java on March 03 and another case in Banten on March 06, 2020. The spatial-temporal results show that all provinces in Indonesia experienced confirmed COVID-19 cases (Figs 2 and 3) within 41 days since the first confirmed case was reported (March 2nd to April 10th 2020). Generally, Jakarta reported consistently the highest number of new confirmed cases per day (>100 per day). Even though the date of onset for the different outbreaks was different among different provinces (Fig 2), once a case was confirmed, new cases followed immediately afterwards.

The heat map (Fig 3) shows the development of transmission in the 34 provinces across Indonesia within this period of approximately 6 months (5 months and 2 weeks). During the first week, the confirmed cases were concentrated only in West Java, Jakarta, and Banten. The following week, new confirmed cases were reported in East Kalimantan, and a few days later the spread of new infections was increasing rapidly both in the western and eastern part of Indonesia, adding 18 new provinces with reported cases. By the sixth week, confirmed cases were noted across all provinces. Within the last 2 weeks of the period studied, cumulative cases of >100 confirmed cases had occurred in several provinces, leaving Jakarta as the most infected area with >1000 cases by the end of the last week (Fig 4).

Discussion

Overall, our study shows that the RT-PCR confirmed SARS-CoV-2 infections in Indonesia were more prevalent in males with age range between 31–45 years old, most presenting with self-reported fever and cough symptoms, and having a prior clinical history of hypertension and/or of diabetes mellitus. The highest increase in the absolute amount of new confirmed cases was shown in Jakarta, West Java, Central Java, East Java, and South Sulawesi; while other provinces showed a comparatively modest reporting of new confirmed cases every day. By the sixth week of follow-up all provinces in Indonesia were affected by confirmed COVID-19 cases. Similar transmission patterns were seen in 5 major cities in China, not geographically adjacent to Wuhan [19].

The characteristics of Indonesian COVID-19 patients were similar to those reported for China and Italy [20–22], with cough and fever/history of fever being the most frequent symptoms [20, 23] and within similar age groups [23, 24]. Males were more prevalent to a worse clinical outcome as compared to females as in other studies from China, Italy and the USA [20, 25, 26]. The elderly population of above 60 years old (19.8%; 326/1,647) showed the highest mortality, in line with observations in other countries [20–22]. Thus, current observations in Indonesia are aligned with previously published observations [27] and show similar patient profiles from other parts of South-East Asia [28–31]. Furthermore, as Indonesia reports one of the highest chronic kidney disease incidences in South-East Asia, affecting over 8% of the over
Table 2. Risk factors (according to sex, age group and main island) for mortality of COVID-19 in Indonesia from March 2nd – August 2nd 2020.

| Risk Factors                  | Confirmed (n) | % Death (n) | % death to total confirmed | Recovered (n) | % recovered to total confirmed | Univariable OR (Death) | Univariable OR (Recovered) |
|-------------------------------|---------------|-------------|----------------------------|---------------|--------------------------------|-----------------------|---------------------------|
| All                           | 111,450       | 5,382       | 4.83                       | 75,551        | 67.79                          | 1                     | 1                         |
| Sex                           |               |             |                            |               |                                |                       |                           |
| Female                        | 51,948        | 2,127       | 4.09                       | 35,532        | 68.05                          | 1.376 (1.300, 1.457)   | 0.727 (0.686, 0.769)     |
| Male                          | 56,300        | 3,146       | 5.59                       | 37,977        | 67.45                          | 1                     | 1                         |
| Age Group (y.o)               |               |             |                            |               |                                |                       |                           |
| 0–5                           | 2,507         | 51          | 2.03                       | 1,723         | 68.73                          | 1                     | 1                         |
| 6–18                          | 7,197         | 59          | 0.82                       | 5,169         | 71.82                          | 0.386 (0.364, 0.563)   | 2.393 (1.776, 3.787)     |
| 19–30                         | 24,557        | 239         | 0.97                       | 17,108        | 69.67                          | 0.472 (0.347, 0.641)   | 2.119 (1.560, 2.878)     |
| 31–45                         | 33,132        | 786         | 2.37                       | 22,987        | 69.38                          | 1.155 (0.867, 1.540)   | 0.866 (0.649, 1.154)     |
| 46–59                         | 26,000        | 2,039       | 7.84                       | 17,238        | 66.30                          | 3.996 (3.013, 5.299)   | 0.250 (0.189, 0.332)     |
| ≥60                           | 12,396        | 2,041       | 16.46                      | 7,474         | 60.29                          | 9.226 (6.954, 12.241)  | 0.108 (0.082, 0.144)     |
| Main Island                   |               |             |                            |               |                                |                       |                           |
| Maluku & Papua Islands        | 6,266         | 111         | 1.77                       | 3,493         | 55.75                          | 1                     | 1                         |
| Sulawesi Island               | 14,837        | 527         | 3.55                       | 10,369        | 69.89                          | 1.599 (1.299, 1.970)   | 0.625 (0.508, 0.770)     |
| Kalimantan Island             | 10,156        | 436         | 4.29                       | 6,721         | 66.18                          | 2.041 (1.651, 2.524)   | 0.490 (0.396, 0.606)     |
| Sumatera Island               | 10,785        | 498         | 4.62                       | 6,070         | 56.28                          | 2.582 (2.093, 3.185)   | 0.387 (0.314, 0.478)     |
| Java & Bali Islands           | 69,396        | 3,810       | 5.49                       | 48,898        | 70.46                          | 2.452 (2.024, 2.970)   | 0.408 (0.337, 0.494)     |
| Month                         |               |             |                            |               |                                |                       |                           |
| March                         | 868           | 148         | 17.05                      | 706           | 81.34                          | 0.445 (0.367, 0.540)   | 2.247 (1.852, 2.726)     |
| April                         | 8,444         | 707         | 8.37                       | 7,577         | 89.73                          | 0.311 (0.258, 0.376)   | 3.213 (2.661, 2.881)     |
| May                           | 16,251        | 967         | 5.95                       | 14,823        | 91.21                          | 0.312 (0.260, 0.375)   | 3.203 (2.665, 3.849)     |
| June                          | 29,795        | 1,694       | 5.69                       | 25,882        | 86.87                          | 0.314 (0.261, 0.377)   | 3.186 (2.651, 3.929)     |
| July                          | 52,371        | 1,700       | 3.25                       | 25,839        | 49.34                          | 2.015 (1.442, 2.815)   | 0.496 (0.355, 0.693)     |
| August                        | 3,104         | 68          | 2.19                       | 161           | 5.19                           | 1.153 (1.023, 1.309)   | 0.585 (0.467, 0.738)     |
| Total Comorbidities           |               |             |                            |               |                                |                       |                           |
| None                          | 5,246         | 186         | 15.95                      | 786           | 67.41                          | 6.550 (5.263, 8.153)   | 0.153 (0.123, 0.190)     |
| One                           | 1,166         | 186         | 15.95                      | 786           | 67.41                          | 6.550 (5.263, 8.153)   | 0.153 (0.123, 0.190)     |
| Two                           | 312           | 108         | 34.62                      | 200           | 64.1                           | 14.947 (11.322, 19.732)| 0.067 (0.051, 0.088)    |
| Three or more                 | 113           | 58          | 51.33                      | 55            | 48.67                          | 29.190 (19.605, 43.461)| 0.034 (0.023, 0.051)    |
| Type of Comorbidity           |               |             |                            |               |                                |                       |                           |
| Hypertension                  | 700           | 182         | 26.00                      | 509           | 72.71                          | 6.034 (4.922, 7.398)   | 0.166 (0.135, 0.203)     |

(Continued)
65 population group, this is likely to further compound the observed mortality rate in that population group as a linked underlying health condition [32].

The COVID-19 vulnerable groups definition includes elderly people, people who are ill and have comorbidities, homeless or under-housed people, as well as people who might struggle economically and psychologically [33]. Children and younger adults represent the smallest proportion of confirmed cases in Indonesia, in line with national reports elsewhere [34, 35]. As this is an inclusive national surveillance system, there is no particular systemic bias for the exclusion of particular vulnerable groups, children or bias in the recording of cases, other than the latter are probably asymptomatic or less symptomatic than other population groups. However, this hypothesis would still need to be verified clinically by the purposive sampling of this age group.

The increase in confirmed cases also reflects the increased availability of testing nationally, as the Indonesian Government allowed both governmental and non-governmental laboratories to perform confirmatory RT-PCR analyses, increasing the national diagnostic capacity [36–38]. By April 29th 2020, there were in total 89 laboratories that have been appointed to examine the suspected patient samples, consisting of 48 hospital laboratories, 15 university laboratories, 18 Ministry of Health laboratories, and 3 from the Directorate of Livestock [36].

The Governor of Jakarta enacted Large Scale Social Distancing starting on April 10th 2020 (40 days after the first confirmed COVID-19 case was reported). This initiative was followed by West Java’s Governor applying the same regulations in satellite cities near Jakarta. The effectiveness of the timing as well as the implementation of these regulations should be evaluated at a later point, however it can be said that they eventually (within 3–4 weeks) led to the plateau of the reported transmission rate within these cities. These measures were coupled with individual-level preventive and hygiene actions strongly advised by the Indonesian Government [39].

### Table 2. (Continued)

| Risk Factors                | Confirmed (n) | % | Death (n) | % death to total confirmed | Recovered (n) | % recovered to total confirmed | Univariable OR (Death) | Univariable OR (Recovered) |
|-----------------------------|---------------|---|-----------|----------------------------|--------------|-------------------------------|------------------------|----------------------------|
| Diabetes mellitus           | 478           | 0.43 | 162       | 33.89                      | 311          | 65.06                     | 8.273 (6.647, 10.296)  | 0.121 (0.97, 0.150) |
| Heart disease               | 276           | 0.25 | 106       | 38.41                      | 168          | 60.87                     | 9.029 (6.936, 11.754)  | 0.111 (0.85, 0.1444)  |
| COPD                        | 139           | 0.12 | 34        | 24.46                      | 105          | 75.54                     | 4.037 (2.710, 6.014)  | 0.248 (0.166, 0.369)  |
| Other respiratory disease   | 89            | 0.08 | 24        | 26.97                      | 63           | 70.79                     | 3.581 (2.212, 5.798)  | 0.279 (0.172, 0.452)  |
| CKD                         | 83            | 0.07 | 43        | 51.81                      | 40           | 48.19                     | 13.745 (8.842, 21.366) | 0.073 (0.047, 0.113)  |
| TB                          | 26            | 0.02 | 7         | 26.92                      | 19           | 73.08                     | 3.389 (1.416, 8.110)  | 0.295 (0.123, 0.706)  |
| Pregnancy                   | 68            | 0.06 | 3         | 4.41                       | 56           | 82.35                     | 1.274 (0.546, 2.972)  | 0.785 (0.337, 1.831)  |
| Asthma                      | 33            | 0.03 | 5         | 15.15                      | 28           | 84.85                     | 1.642 (0.631, 4.275)  | 0.609 (0.234, 1.586)  |
| Cancer                      | 21            | 0.02 | 7         | 33.33                      | 14           | 66.67                     | 5.993 (2.407, 14.918) | 0.167 (0.067, 0.415)  |
| Immunocompromise            | 21            | 0.02 | 7         | 33.33                      | 14           | 66.67                     | 6.001 (2.411, 14.939) | 0.167 (0.067, 0.415)  |
| Liver disease               | 28            | 0.03 | 8         | 28.57                      | 20           | 71.43                     | 4.806 (2.106, 10.969) | 0.208 (0.091, 0.475)  |

https://doi.org/10.1371/journal.pone.0243703.t002
The strength of our study is that the data was collected centrally by the Indonesia National Task Force for the Acceleration of COVID-19. Therefore, this made the uniform in the way of reporting, and able to cover thoroughly the entire national area of Indonesia. However, this study has certain limitations. The very high level of incomplete data (in some cases close to

Fig 1. a. Classification of status according to age group in 8 priority provinces in Indonesia from March 2nd–August 2nd 2020. b. Classification of patients’ status according to sex in 8 priority provinces in Indonesia from March 2nd–August 2nd 2020. c. Incidence of death cases by week due to COVID-19 in Indonesia from March 2nd–August 2nd 2020.

https://doi.org/10.1371/journal.pone.0243703.g001

Fig 2. New confirmed cases per day in 34 provinces in Indonesia from March 2nd–August 2nd 2020.

https://doi.org/10.1371/journal.pone.0243703.g002
Fig 3. Distribution map of Covid-19 cumulative cases in Indonesia from March 2nd – August 2nd 2020.

https://doi.org/10.1371/journal.pone.0243703.g003
90%) and the high variability of completion between different comorbidity categories has prevented the further analyses of comorbidities. The level of completion (Table 2) is an aspect currently addressed by the Indonesian authorities. Furthermore, there were delays in the reporting of data, either due to the lack of staff confidence in the initial handling of the reports or more likely because of the overwhelmed data management structure at the local levels of administration. Furthermore, the data was not always complete, and did not provide patient’s history of social contact, while symptoms, such as cough and prior fever episodes were self-reported, making them prone to memory bias. As Indonesia is a very active transit hub in South-East Asia, there is a likelihood that a number of the confirmed COVID-19 cases might be imported from other nations regionally, however the type of data collected so far does not allow to differentiate local transmission events vs imported seeding from other areas.

**Conclusion**

This study is the first to provide detailed characteristics of the laboratory confirmed COVID-19 patients in Indonesia and used a spatial-temporal analysis to present the transmission pattern from the very beginning of the outbreak in Indonesia on March 2nd 2020 to August 2nd 2020. The demographic profile of confirmed infected patients reported in this manuscript is in keeping with the confirmed patient profiles from other parts of South-East Asia. As in other neighbouring geographical areas (Vietnam, Thailand and Malaysia) the first confirmed cases were directly related to travellers from other infection hotspots. In the case of Indonesia, it is thought to have arrived from travellers returning from an affected area in Malaysia, as reported widely in the press [40]. However, without genomic or further laboratory information this remains an informed conjecture.

The data reported here, demonstrates that all the provinces of Indonesia were affected by COVID-19 within a short time period. The incidence on Java island is not surprising given its very high population density and population movement. The increase of new confirmed cases has been consistent during this time period for all provinces, in part due to the surge in national diagnostic capacity. This information is utilized continuously by the current Indonesian Task Force in their efforts to ultimately manage the outbreak.

**Acknowledgments**

**Disclaimer:** Where authors are identified as personnel of the International Agency for Research on Cancer/WHO, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/WHO.
Author Contributions

Conceptualization: Siswanto, Wiku Adisasmito.

Data curation: Chyntia Aryanti Mayadewi, Siswanto.

Formal analysis: Chyntia Aryanti Mayadewi, Zisis Kozlakidis, Siswanto, Wiku Adisasmito.

Methodology: Chyntia Aryanti Mayadewi, Haniena Diva, Siswanto, Wiku Adisasmito.

Project administration: Chyntia Aryanti Mayadewi, Haniena Diva.

Resources: Siswanto.

Supervision: Wiku Adisasmito.

Visualization: Haniena Diva.

Writing – original draft: Dewi Nur Aisyah, Haniena Diva, Zisis Kozlakidis.

Writing – review & editing: Dewi Nur Aisyah, Zisis Kozlakidis, Wiku Adisasmito.

References

1. World Health Organization, Coronavirus Disease 2019 (COVID-19) Weekly Epidemiological Update (WHO, 2020); Geneva, August 23, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200824-weekly-epi-update.pdf?sfvrsn=806986d1_4 [Accessed August 23, 2020]

2. Liu Ying, Albert A Gayle Annelies Wilder-Smith, Joacim Rocklöv, The reproductive number of COVID-19 is higher compared to SARS coronavirus, *Journal of Travel Medicine*, Volume 27, Issue 2, March 2020, taaa021, https://doi.org/10.1093/jtm/taaa021 PMID: 32052846

3. Li R, Pei S, Chen B, Song Y, Zhang T, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science; 01 MAY 2020; 368(6490): 489–493. https://doi.org/10.1126/science.abb3221 PMID: 32179701

4. A Wilder-Smith MD, D O Freedman MD, Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak, *Journal of Travel Medicine*, Volume 27, Issue 2, March 2020, taaa020, https://doi.org/10.1093/jtm/taaa020 PMID: 32052841

5. Benjamin J Cowling, Allison E Aiello, Public Health Measures to Slow Community Spread of Coronavirus Disease 2019, *The Journal of Infectious Diseases*, jiaa123, https://doi.org/10.1093/infdis/jiaa123

6. World Health Organization. Critical preparedness, readiness and response actions for Covid-19: Interim guidance, 22 March 2020. https://www.who.int/publications-detail/critical-preparedness-readiness-and-response-actions-for-covid-19 [Accessed May 9, 2020]

7. Setiati S, Azwar MK. (2020) COVID-19 and Indonesia. Acta Med Indones-Indones J Intern Med; 52(1): 84–89.

8. World Health Organization. COVID-19 Strategy Update.14 April 2020. https://www.who.int/publications-detail/strategic-preparedness-and-response-plan-for-the-new-coronavirus [Accessed 9 May 2020]

9. Tsang TK, Wu P, Lin Y, Lau EHY, Leung GM, Cowling BJ. Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study, The Lancet Public Health; 5(5): e289–e296. https://doi.org/10.1016/S2468-2667(20)30089-X PMID: 32330458

10. Konstantinoudis G, Schuhmacher D, Rue H, Spycher BD. Discrete versus continuous domain models for disease mapping, Spat Spatio-temporal Epidemiol. 2020; 32:100319 https://doi.org/10.1016/j.sste.2019.100319 PMID: 32007264

11. Nanni M, Raffaeta A, Renso C and Turini F., “Deductive and Inductive Reasoning on Spatio-Temporal Data” in Applications of declarative programming and knowledge management, Berlin: Springer Berlin / Heidelberg, vol. 3392, pp. 98–115, 2005 g8bu

12. Government of Indonesia. Indonesian Ministry of Health, 2020. List of COVID-19 Reference Hospitals in Indonesia. file:///C:/Users/kozlakidisz/Downloads/Daftar_RS_rujukan_COVID-19%20(1).pdf [Accessed 9 May, 2020]
13. The World Bank. Population, female (% of total population–Indonesia) https://data.worldbank.org/indicator/SP.POP.TOTL.FE.ZS?locations=ID [Accessed 9 May, 2020]

14. Sri Moertiningsih Adiotoemo and Ghazy Mujahid (ed. Horst Posselt). United Nations Population Fund (UNFPA). UNFPA Indonesia Monograph Series No 1. Indonesia on the Threshold of Population Ageing. July 2014, Jakarta, Indonesia. https://indonesia.unfpa.org/sites/default/files/pub-pdf/BUKU_Monograph_No1_Ageing_03_Low-res.pdf [Accessed May 9, 2020]

15. Indonesian Government. Task Force for the Acceleration of Handling of COVID-19. Guidelines for the Prevention and Control of Coronavirus Disease (COVID-19). https://www.sumutprov.go.id/content/userfiles/REV-05_Pedoman_P2_COVID-19_13_Juli_2020_compressed.pdf [Accessed August 23, 2020]

16. Sperandei S. (2014). Understanding logistic regression analysis. *Biochemical and Biophysical Research Communications*, 24(1), 12–18.

17. Al-Rousan N., & Al-Najjar H. (2020). Data Analysis of Coronavirus CoVID-19 Epidemic in South Korea Based on Recovered and Death Cases. *Journal of Medical Virology*. 92(9): 1603–1608. https://doi.org/10.1002/jmv.25850 PMID: 32270521

18. Voorrips R. E., MapChart: Software for the Graphical Presentation of Linkage Maps and QTLs, *Journal of Heredity*, January 2002; 93(1): 77–78 10.1093/jhered/93.1.77 PMID: 12011185

19. Liu Y. et al., What are the underlying transmission patterns of COVID-19 outbreak? An age-specific social contact characterization, *EClinicalMedicine* (2020), https://doi.org/10.1016/j.eclinm.2020.100354 PMID: 32313879

20. Guan W, Ni Z, Hu Y, Liang W, Ou C, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med. 2020; 382: 1708–20.

21. Zhu J., Li P., Pang J., Zhong Z., Li H., He C., et al.Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis J Med Virol (2020), https://doi.org/10.1002/jmv.25884 PMID: 32298251

22. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020; 323(16):1574–1581 https://doi.org/10.1001/jama.2020.5394 PMID: 32250385

23. Wenham C, Smith J, Morgan R, et al. COVID-19: the gendered impacts of the outbreak. The Lancet. 2020; 395(10227): 846–848. 10.1016/S0140-6736(20)30526-2 PMID: 32151325

24. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z et al. Characteristics of COVID-19 infection in Beijing. Journal of Infection. 2020; 80(4):401–406. https://doi.org/10.1016/j.jinf.2020.02.018

25. Flavia R, Marco A, Xanthi A, Antonino B, Martina DM, Massimo F, et al. Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic. medRxiv 2020.04.08.20056861; https://doi.org/10.1101/2020.04.08.20056861

26. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:458–464. https://doi.org/10.15585/mmwr.mm6915e3 PMID: 32298251

27. Mahase E. Covid-19: death rate is 0.66% and increases with age, study estimates BMJ 2020; 369: m1327 https://doi.org/10.1136/bmj.m1327 PMID: 32238354

28. Wang D.W., Hu B., Hu C., Zhu F., Liu X. et al. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan, China. JAMA 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585 PMID: 32031570

29. Huang C.L., Wang Y.M., Li X.W., Ren L., Zhao J. et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (10223 ), 497–506. https://doi.org/10.1016/ S0140-6736(20)30183-5 PMID: 31986264

30. Nguyen THD, Vu DC. Summary of the COVID-19 outbreak in Vietnam—Lessons and suggestions. Travel Med Infect Dis. 2020 Apr 2:101651. https://doi.org/10.1016/j.tmaid.2020.101651 Epub ahead of print. PMID: 32247928

31. Okada P, Buathong R, Phuygun S, Thanadachakul T, Parmsen S, Wongboot W, et al. Early transmission patterns of coronavirus disease 2019 (COVID-19) in travellers from Wuhan to Thailand, January 2020. Euro Surveill. 2020 Feb; 25(8):2000097. https://doi.org/10.2807/1560-7917.S.2020.25.8.2000097

32. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the 106 receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 107 2019-nCoV infection. Frontiers of medicine [Internet]. 2020 Mar 12; Available from: 108 http://www.ncbi.nlm.nih.gov/pubmed/32170560

33. Redefining vulnerability in the era of COVID-19. Lancet editorial. 2020; 395(10230): 1089. https://doi.org/10.1016/S0140-6736(20)30757-1 PMID: 32247378
34. Kelvin AA, Halperin S. COVID-19 in children: the link in the transmission chain. The Lancet Infect Dis 2020 S1473-3099(20): 30198–5 https://doi.org/10.1016/S1473-3099(20)30236-X PMID: 32220651

35. Morand A., Fabre A., Minodier P., Boutin A., Vanel N., Bosdure E., et al. COVID-19 virus and children: What do we know? Archives de Pédiatrie. 2020; 27(3): 117–118 https://doi.org/10.1016/j.arcped.2020.03.001 PMID: 32253003

36. Indonesian Government. Task Force for the Acceleration of Handling of COVID-19. ‘A total of 89 active laboratories allowed to check for COVID-19’ Press Bulletin. April 29, 2020. https://covid19.go.id/p/berita/sebanyak-89-laboratorium-aktif-periksa-covid-19 [Accessed May 9 2020]

37. ‘Government adds 41 laboratories to Covid-19, now totaling 89’. Kompas.com. Online news agency, 29 April 2020. https://nasional.kompas.com/read/2020/04/29/17120861/pemerintah-tambah-41-laboratorium-untuk-covid-19-kini-jadi-89 [Accessed May 9, 2020]

38. Lippi G., & Plebani M. (2020). The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks, Clinical Chemistry and Laboratory Medicine (CCLM) (published online ahead of print), 20200240

39. Indonesian Ministry of Health. Guidelines for the Prevention and Control of COVID-19. July 2020. https://covid19.go.id/storage/app/media/Protokol/REV-05_Pedoman_P2_COVID-19_13_Juli_2020.pdf. [Accessed September 3, 2020]

40. Indonesian News Agency. Jakarta Globe News. https://jakartaglobe.id/news/indonesia-confirms-first-coronavirus-cases-in-its-territory/ [Accessed May 9, 2020]